<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Danaparoid (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Danaparoid (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Danaparoid (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12353" href="/d/html/12353.html" rel="external">see "Danaparoid (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866502"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Orgaran</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F156590"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticoagulant</li></ul></div>
<div class="block doa drugH1Div" id="F156563"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> A different parenteral anticoagulant may be preferred; long half-life and irreversibility of danaparoid make other parenteral agents more desirable if quick offset of anticoagulant activity is desired. Dosing recommendations are expressed as anti-Xa units per manufacturer labeling unless otherwise noted.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc0348fd-ab88-4c57-918f-f29ea99d9572">Catheter patency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catheter patency:</b> Mix 750 units with 50 mL normal saline. Flush catheter with 5 to 10 mL of resulting solution as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8a25e7c3-a044-4d71-9686-d90a03733621">Deep vein thrombosis prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Orthopedic, major abdominal, or thoracic surgery:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b> 750 units every 12 hours for up to 14 days; it is recommended that patients begin prophylactic therapy preoperatively and receive their last preoperative dose 1 to 4 hours before surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Nonhemorrhagic stroke:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: Bolus up to 1,000 units as single dose followed by SUBQ maintenance dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b> Maintenance: After IV bolus dose, administer 750 units every 12 hours for 7 to 14 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="268855ac-c424-450c-ab52-a51bfe383ea4">Heparin-induced thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In addition to the indications below, danaparoid may be used for various procedures and/or surgeries in the setting of heparin induced thrombocytopenia (HIT) (eg, perioperative venous thromboembolism prophylaxis, cardiac procedures, peripheral vascular bypass, cardiopulmonary bypass, and hemodialysis). Refer to manufacturer's labeling for dosing in these situations. However, a different anticoagulant may be preferred due to danaparoid’s long half-life and irreversibility.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Deep vein thrombosis prophylaxis (with current or past heparin-induced thrombocytopenia) in nonsurgical patients:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Dosing based on manufacturer’s labeling; may not reflect clinical practice. In patients with current (acute) HIT, therapeutic dose rather than prophylactic dose anticoagulation is recommended for at least 4 weeks and up to 3 months (ACCP [Linkins 2012]; ASH [Cucker 2018]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV bolus (optional):</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Current HIT (&lt;3 months ago): </i>May administer an initial IV bolus of 1,250 units to rapidly attain prophylaxis levels (if clinically necessary) or may initiate maintenance SUBQ regimen without a bolus as follows:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Past HIT (&gt;3 months ago):</i> IV bolus not recommended<b>.</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ (maintenance)</b>:</p>
<p style="text-indent:-2em;margin-left:10em;">≤90 kg:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Current HIT or past HIT</i>: 750 units every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;90 kg:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Current HIT (&lt;3 months ago)</i>: 1,250 units every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Past HIT (&gt;3 months ago)</i>: 1,250 units every 12 hours or 750 units every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Treatment of deep vein thrombosis or pulmonary embolism</b>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initial:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Thrombosis &lt;5 days old</i>: Administer weight-based IV bolus followed by maintenance IV infusion <b>or</b> maintenance SUBQ injections (weight-based dosing).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV bolus:</b></p>
<p style="text-indent:-2em;margin-left:12em;">≤55 kg: 1,250 to 1,500 units.</p>
<p style="text-indent:-2em;margin-left:12em;">55 to 90 kg: 2,250 to 2,500 units.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;90 kg: 3,750 units.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Thrombosis ≥5 days old</i>: <b>IV bolus:</b> 1,250 units (regardless of weight) followed by maintenance SUBQ injections.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Thrombosis &lt;5 days old:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV infusion </b>(after IV bolus administered): 400 units/hour for 4 hours, then 300 units/hour for 4 hours, then 150 to 200 units/hour; adjust rate according to target anti-Xa levels. <b>Note:</b> IV infusion dose is not weight-based.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>or</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>SUBQ</b> (after IV bolus administered):</p>
<p style="text-indent:-2em;margin-left:12em;">≤55 kg: 1,500 units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">55 to 90 kg: 2,000 units every 12 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;90 kg: 1,750 units every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Thrombosis ≥5 days old</i>:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>SUBQ</b>:</p>
<p style="text-indent:-2em;margin-left:12em;">≤90 kg: 750 units every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;90 kg: 750 units every 8 hours or 1,250 units every 8 to 12 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion to oral anticoagulant therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Establish adequate antithrombotic effect with danaparoid prior to initiation of oral anticoagulant therapy. Laboratory values (eg, PT/INR) taken within 5 hours of danaparoid administration may be unreliable.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion of SUBQ danaparoid to warfarin (based on current danaparoid dose):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Danaparoid 750 units every 12 hours: Initiate warfarin and maintain danaparoid therapy until PT/INR is therapeutic; may take up to 5 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Danaparoid 1,250 units every 12 hours: Initiate warfarin and decrease danaparoid to 750 units every 12 hours; maintain danaparoid therapy until PT/INR is therapeutic; may take up to 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion of IV danaparoid to warfarin:</i> Initiate warfarin with concurrent danaparoid IV infusion (maximum 300 units/hour); discontinue IV infusion once INR is therapeutic (maximum INR: 3.0). If bleeding risk is present, IV infusion should be reduced to 75 units/hour and warfarin initiation withheld for 24 hours <b>or</b> danaparoid IV infusion may be switched to SUBQ route at a dose of 1,250 units every 12 hours and the recommended conversion of SUBQ danaparoid to warfarin regimen followed (ie, subsequent reduction to 750 units every 12 hours while warfarin is initiated).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990741"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Danaparoid half-life is significantly prolonged in renal impairment; anti-Xa levels should be closely monitored. Dosage reduction, especially with maintenance doses, may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment: There are no dosage adjustments provided in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (serum creatinine ≥220 micromol/L [≥2.5 mg/dL]): Following initial dose, dose reductions or temporary discontinuation of therapy may be necessary to prevent accumulation of plasma anti-Xa (indicated by consistent, steady state-plasma anti-Xa activity &gt;0.5 anti-Xa units).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 1,500 to 3,750 units before dialysis session. <b>Note:</b> Dose depends on frequency of dialysis regimen (eg, daily dialysis vs every-other-day or less frequently) and weight of patient with the lower dose recommended for patients &lt;55 kg. Do not administer prior to dialysis if plasma antifactor Xa levels &gt;400 units/L and not receiving daily dialysis; however, if fibrin threads are present in bubble chamber may administer 1,500 units.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemofiltration: IV: 55 to 90 kg: 2,500 units as a bolus, followed by 600 units/hour for 4 hours, then 400 units/hour for 4 hours, then 200 to 600 units/hour to maintain adequate anti-Xa levels. <b>Note:</b> If patient is &lt;55 kg, reduce bolus dose to 2,000 units, followed by 400 units/hour for 4 hours, then 150 to 400 units/hour to maintain anti-Xa levels of 500 to 1,000 units/L.</p></div>
<div class="block doha drugH1Div" id="F50988111"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F156564"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F156536"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (2%), nausea (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukocytosis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Hematoma at injection site (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Increased serum lipase (lipoprotein and triglyceride)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, urinary tract hemorrhage (including microscopic)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise, hematoma, hemorrhage, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Delayed hypersensitivity reaction (injection site: eczematous plaques) (Blickstein 2003, Szolar-Platzar 2000)</p></div>
<div class="block coi drugH1Div" id="F156550"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to danaparoid, or any component of the formulation (including sulfites); history of thrombocytopenia while receiving danaparoid or when associated with a positive <i>in vitro</i> test for antiplatelet antibodies in the presence of danaparoid; hemorrhagic stroke (without systemic emboli); history of thrombosis with danaparoid; acute hemorrhagic stroke; major blood clotting disorder; uncontrollable active bleeding state; severe hemorrhagic diathesis; acute or subacute bacterial endocarditis; active gastric or duodenal ulcer; surgery of CNS, eyes, or ears; diabetic or hemorrhagic retinopathy; severe uncontrolled hypertension; other conditions or diseases that increase risk of hemorrhage; not for intramuscular use</p></div>
<div class="block war drugH1Div" id="F156533"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding (eg, severe hepatic disease, patients undergoing knee surgery or other invasive procedures, concomitant therapy with platelet inhibitors, elderly). Discontinue if bleeding occurs. <b>Note:</b> Routine clotting assays are not suitable for monitoring danaparoid anticoagulant activity; determining anti-factor Xa levels is the only available method but may not correlate with efficacy. Danaparoid is <b>not</b> effectively antagonized by protamine sulfate. No other antidote is available, so extreme caution is needed in monitoring dose given and resulting factor Xa inhibition effect. Plasmapheresis may be effective in reducing anti-Xa levels in emergency situations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Monitor for hyperkalemia. Heparin can cause hyperkalemia by affecting aldosterone; similar reactions could occur with danaparoid.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients with a history of peptic ulcer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prosthetic heart valves: Safety and efficacy have not been established for use as thromboprophylaxis in patients with prosthetic heart valves.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment; primarily renally eliminated. Dosage adjustment may be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stroke: Hemorrhagic stroke should be ruled out by CT scan prior to initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia: Use caution in patients with or with a history of thrombocytopenia (heparin-induced, congenital) or platelet defects. The manufacturer labeling recommends that patients with a history of heparin-induced thrombocytopenia be tested for cross-reactivity with danaparoid prior to initiating therapy; if test is positive, alternative therapy should be employed unless otherwise not available. If danaparoid is administered, therapy must be discontinued immediately with clinical signs of positive cross-reactivity (eg, increased reduction in platelet counts, thrombosis, skin necrosis). May resume therapy (if needed) only after laboratory confirmed negative test for danaparoid activated antiplatelet antibodies. Cutaneous allergy tests may help detect the presence of cross-reactivity between heparins and danaparoid (Grassegger 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium sulfite: This product contains sodium sulfite which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people; this is seen more frequently in asthmatics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuraxial anesthesia: <b>Spinal or epidural hematomas, including subsequent paralysis, may occur with recent or anticipated neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients anticoagulated with LMWH or heparinoids.</b> Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis, the use of indwelling epidural catheters for analgesia, a history of spinal deformity or spinal surgery, as well as a history of traumatic or repeated epidural or spinal punctures. Spinal procedures should be avoided for 12 hours after the last danaparoid dose; allow at least 2 hours after procedure before resuming danaparoid therapy. Patient should be observed closely for bleeding and signs and symptoms of neurological impairment if therapy is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia, or spinal anesthesia.</p></div>
<div class="block prod-avail drugH1Div" id="F11218429"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040721"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F52866503"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orgaran: 750 units/0.6 mL (0.6 mL) [contains sodium sulfite]</p></div>
<div class="block adm drugH1Div" id="F802622"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV, SUBQ:</b> May administer intravenously as bolus or infusion, or by subcutaneous injection. When administered intravenously, do not mix with other drugs. For subcutaneous administration, rotate injection sites. Do <b>not </b>administer intramuscularly.</p></div>
<div class="block use drugH1Div" id="F156547"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Catheter patency:</b> Intermittent flushing to maintain patency of catheters/IV lines and/or access ports.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis prophylaxis: </b>Prevention of postoperative deep vein thrombosis (DVT) following orthopedic or major abdominal and thoracic surgery; prevention of DVT in patients with confirmed diagnosis of nonhemorrhagic stroke.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia:</b> Management of heparin-induced thrombocytopenia (HIT).</p></div>
<div class="block mst drugH1Div" id="F6052981"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Orgaran may be confused with argatroban</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299123"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F156538"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with other anticoagulants prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oritavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13161901"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The manufacturer labeling states that incidental observations in pregnant women during the last trimesters, gave no indication that use during pregnancy results in fetal abnormalities or exacerbation of bleeding in the mother or infant during delivery. Use in pregnant women however is generally not recommended unless deemed medically necessary and alternative therapy is unavailable. Danaparoid does not cross the placenta and is the preferred anticoagulant in pregnant women with HIT (Guyatt 2012).</p></div>
<div class="block brc drugH1Div" id="F13161913"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">Only low amounts of anti-Xa activity have been found breast milk following maternal use of danaparoid; however, because it is not absorbed when taken orally, it is unlikely to cause adverse events in a breastfeeding infant. Use of danaparoid may be continued in breastfeeding (Guyatt 2012). The manufacturer labeling recommends that women receiving danaparoid avoid breast-feeding.</p></div>
<div class="block mop drugH1Div" id="F156542"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Platelets (baseline, every other day during week 1, twice weekly during weeks 2 and 3, and once weekly thereafter); occult blood or other signs of bleeding; anti-Xa activity (if available). See manufacturer’s recommendations within labeling regarding anticipated anti-Xa levels.</p></div>
<div class="block pha drugH1Div" id="F156532"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits factor Xa and IIa (anti-Xa effects &gt;20 times anti-IIa effects). Prevents fibrin formation in the coagulation pathway via thrombin generation inhibition. </p></div>
<div class="block phk drugH1Div" id="F156549"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Peak effect: SubQ: Maximum antifactor Xa activities occur in 4-5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: SubQ: ~100%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Anti-Xa activity: ~25 hours (renal impairment: 29-35 hours); Thrombin generation inhibition activity: ~7 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F156552"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Danaparoid | Orgaran</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Orgaran</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Orgaran</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Orgaran</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Orgaran</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Orgaran</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30482768">
<a name="30482768"></a>Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Adv</i>. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danaparoid-united-states-not-available-drug-information/abstract-text/30482768/pubmed" id="30482768" target="_blank">30482768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11231243">
<a name="11231243"></a>Grassegger A, Fritsch P, and Reider N, “Delayed-Type Hypersensitivity and Cross-Reactivity to Heparins and Danaparoid: A Prospective Study,” <i>Dermatol Surg</i>, 2001, 27(1):47-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danaparoid-united-states-not-available-drug-information/abstract-text/11231243/pubmed" id="11231243" target="_blank">11231243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danaparoid-united-states-not-available-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315270">
<a name="22315270"></a>Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(suppl 2):e495S-e530S. doi:10.1378/chest.11-2303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/danaparoid-united-states-not-available-drug-information/abstract-text/22315270/pubmed" id="22315270" target="_blank">22315270</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Orgaran (danaparoid) [product monograph DVT]. Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; February 2018.</div>
</li>
<li>
<div class="reference">
                  Orgaran (danaparoid) [product monograph HIT]. Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; February 2018.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9320 Version 156.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
